The company posted a net profit of ₹159 crore, broadly unchanged from a year earlier.
However, the year-ago quarter included an exceptional gain of ₹19.5 crore. Excluding that one-time item, the underlying profit performance was stronger than the headline numbers suggest.
Revenue from operations rose 26.5% year-on-year to ₹1,304 crore from ₹1,030.8 crore.
EBITDA increased 26.3% to ₹286.7 crore from ₹226.9 crore, while the EBITDA margin remained steady at 22%.
Maintaining margins while expanding revenue by more than 25% is a positive sign, as it indicates the company managed growth without sacrificing profitability.
Patient volumes continue to rise
The company said inpatient volumes increased 27.7% year-on-year, while outpatient volumes grew 34.5%.
Occupied bed days rose 21.1%, translating into an occupancy of around 63%, despite the addition of new capacity.
Excluding the relatively new Noida hospital, occupancy stood at 66%.
Higher occupancy means more hospital beds are being utilised, improving revenue generation and helping spread fixed costs across a larger patient base.
Expansion continues across hospitals
Global Health added 72 beds across its network during the quarter, including:
- 51 beds at Noida
- 21 beds at Lucknow
The company also onboarded more than 70 doctors, including over 50 senior clinicians, to strengthen its clinical capabilities.
Adding doctors alongside new beds is crucial for hospitals, as additional capacity can generate revenue only if supported by adequate medical staff.
Noida hospital moves closer to profitability
The company’s Noida hospital continued to improve its financial performance.
It reported total income of ₹855 million, compared with ₹525 million in the March quarter.
Its EBITDA loss narrowed sharply to ₹49 million from ₹236 million.
The rapid reduction in losses suggests the hospital is moving closer to breakeven as patient volumes ramp up—a positive development for future profitability.
International patients and pharmacy business grow
Revenue from international patients increased 23% year-on-year to ₹782 million.
Meanwhile, revenue from the outpatient pharmacy business, including hospital and retail pharmacies, grew 50.9% to ₹609 million.
These businesses provide additional revenue streams beyond hospital admissions and consultations, helping diversify earnings.
Expansion pipeline remains ambitious
Group CEO and Director Pankaj Sahni said the company recorded its highest-ever quarterly revenue and EBITDA, driven by strong patient volumes and better realisations.
He added that the Noida hospital has started making a meaningful contribution while significantly reducing operating losses.
Looking ahead, Global Health expects to operationalise its new 80-bed cancer facility in Indore over the next few months.
The company has also expanded plans for its proposed Guwahati hospital, increasing its capacity to 650 beds.
Overall, Global Health plans to add 2,950 beds across five greenfield projects over the next few years.
The aggressive expansion pipeline signals management’s confidence in sustained demand for quality healthcare services, although these projects will require significant investment before contributing meaningfully to earnings.
Shares of Global Health ended 0.69% lower at ₹1,423 on the National Stock Exchange on Thursday, ahead of the earnings announcement.
Also Read: Pricol Q1 profit jumps 34% as revenue crosses ₹1,100 crore
